Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".

Eli Lilly (NYSE: LLY) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price ...

The United Kingdom’s regulatory body for medicine and health-care products issued a warning for patients using semaglutide – ...

A new Cell Metabolism study finds semaglutide drugs like Ozempic may slow osteoarthritis and protect cartilage through direct ...

Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.

According to the Centers for Disease Control and Prevention (CDC), approximately 42% of Americans are obese, and 65% say willpower alone isn’t enough for most people who are trying to lose weight.

In a new review from top dietitians in Australia, it appears very few global trials of GLP-1s have taken into consideration ...

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...

Hims & Hers last week announced a copycat version of the Wegovy pill that would cost $49 for the first month and $99 per month after on a five-month plan. That sent the stock surging last week, but ...

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing ...

In a research note that made gloomy reading for the bakery chain, Jefferies analysts said the rise of fat jabs could hit ...